Loading…
Disclosed for 94 months, Dec 2018 to Sep 2026.
DSP Healthcare Fund is an active equity fund in the Sectoral / Thematic category from DSP Mutual Fund. In November 2022 it disclosed 24 stocks worth ₹1,265 Cr, up ₹46.1 Cr from Oct 2022. Its largest positions were Sun Pharmaceutical Industries Limited (16.5%), Cipla Limited (9.3%), Apollo Hospitals Enterprise Limited (7.0%); the ten largest together made up 66.0% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 61.2% of its equity. Cash and debt stood at 0.9%. Compared with Oct 2022 the fund entered 0 new stocks and exited 0.
Top-10 weight is higher than 90% of peers
Holds more stocks than 7% of peers
Holds more cash than 11% of peers
What these mean: concentration · cash
Every line the fund disclosed, with the change against Oct 2022. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 16.48% | down 0.15 pts | ₹208 Cr | up ₹5.8 Cr | Added |
| Cipla Limited | 9.33% | down 0.59 pts | ₹118 Cr | down ₹2.9 Cr | Trimmed |
| Apollo Hospitals Enterprise Limited | 6.96% | up 0.06 pts | ₹88 Cr | up ₹3.9 Cr | Added |
| Lupin Limited | 5.42% | up 0.29 pts | ₹68.6 Cr | up ₹6 Cr | Added |
| IPCA Laboratories Limited | 5.42% | down 0.45 pts | ₹68.5 Cr | down ₹2.9 Cr | Trimmed |
| Procter & Gamble Health Limited | 5.22% | down 0.03 pts | ₹66.1 Cr | up ₹2.1 Cr | Added |
| Dr. Reddy's Laboratories Limited | 4.97% | down 0.13 pts | ₹62.8 Cr | up ₹75 L | Added |
| Alkem Laboratories Limited | 4.39% | up 0.04 pts | ₹55.6 Cr | up ₹2.6 Cr | Added |
| Vijaya Diagnostic Centre Limited | 3.94% | up 0.29 pts | ₹49.9 Cr | up ₹5.3 Cr | Added |
| Max Healthcare Institute Limited | 3.88% | down 1.26 pts | ₹49.1 Cr | down ₹13.5 Cr | Trimmed |
| Indoco Remedies Limited | 3.53% | up 0.27 pts | ₹44.7 Cr | up ₹4.9 Cr | Added |
| Abiomed Inc | 3.26% | up 1.00 pts | ₹41.3 Cr | up ₹13.7 Cr | Added |
| Intuitive Surgical Inc | 3.17% | up 0.05 pts | ₹40.1 Cr | up ₹2.1 Cr | Added |
| Globus Medical Inc | 3.09% | up 0.07 pts | ₹39.1 Cr | up ₹2.3 Cr | Added |
| Alembic Pharmaceuticals Limited | 3.02% | up 1.30 pts | ₹38.2 Cr | up ₹17.2 Cr | Added |
| Aarti Drugs Limited | 2.56% | down 0.25 pts | ₹32.4 Cr | down ₹1.9 Cr | Trimmed |
| ICICI Lombard General Insurance Company Limited | 2.31% | down 0.01 pts | ₹29.2 Cr | up ₹99 L | Added |
| Suven Pharmaceuticals Limited | 2.19% | up 0.24 pts | ₹27.7 Cr | up ₹4 Cr | Added |
| Abbott Laboratories | 2.11% | down <0.01 pts | ₹26.7 Cr | up ₹92 L | Added |
| Syngene International Limited | 1.80% | down 0.14 pts | ₹22.8 Cr | down ₹89 L | Trimmed |
| Global X Funds - Global X Genomics & Biotechnology ETF Fund units | 1.67% | down 0.13 pts | ₹21.1 Cr | down ₹76 L | Trimmed |
| Kovai Medical Center and Hospital Limited | 1.62% | up 0.34 pts | ₹20.5 Cr | up ₹4.9 Cr | Added |
| Illumina Inc | 1.11% | down 0.18 pts | ₹14 Cr | down ₹1.7 Cr | Trimmed |
| MedPlus Health Services Limited | 1.04% | up 0.11 pts | ₹13.2 Cr | up ₹1.8 Cr | Added |
| Cash, TREPS & receivables | 0.92% | down 0.76 pts | ₹11.7 Cr | down ₹8.8 Cr | Trimmed |
| Pfizer Limited | 0.55% | up 0.01 pts | ₹7 Cr | up ₹34 L | Added |
None.
None.
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Compared with
Since Oct 2022, the weight rose most in Pharmaceuticals (+0.2 pts) and Retailing (+0.1 pts), and fell most in Pharmaceuticals & Biotechnology (−0.3 pts) and Healthcare Services (−0.1 pts).
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
| Sector | Nov 2019 | Nov 2021 | May 2022 | Aug 2022 | Oct 2022 | Nov 2022 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 69.0% | 56.3% | 56.3% | 56.9% | 61.4% | 61.2% |
| Healthcare Services | 19.1% | 29.0% | 26.4% | 26.0% | 23.3% | 23.2% |
| Healthcare Equipment & Supplies | — | 5.8% | 5.8% | 5.5% | 6.4% | 6.4% |
| Pharmaceuticals | 10.4% | 6.4% | 7.3% | 7.6% | 5.6% | 5.8% |
| Insurance | 1.6% | 2.5% | 2.6% | 2.7% | 2.4% | 2.4% |
| Retailing | — | — | 1.4% | 1.2% | 1.0% | 1.1% |
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
| Jun 2026 |
| ₹3,514 Cr |
| 28 |
| 1 |
| 1 |
| 6.8% |
| 6.8% |
| — |
| May 2026 | ₹3,309 Cr | 28 | 0 | 2 | 6.3% | 6.3% | — |
| Apr 2026 | ₹3,142 Cr | 30 | 0 | 0 | 2.4% | 2.4% | — |
| Mar 2026 | ₹2,892 Cr | 30 | 0 | 0 | 1.5% | 1.5% | — |
| Feb 2026 | ₹3,033 Cr | 30 | 0 | 0 | 1.1% | 1.1% | — |
| Jan 2026 | ₹2,971 Cr | 30 | 0 | 1 | 1.2% | 1.2% | — |
| Dec 2025 | ₹3,114 Cr | 31 | 2 | 0 | 1.0% | 1.0% | — |
| Nov 2025 | ₹3,179 Cr | 29 | 0 | 0 | 2.1% | 2.1% | — |
| Oct 2025 | ₹3,144 Cr | 29 | 0 | 0 | 1.3% | 1.3% | — |
| Sep 2025 | ₹3,074 Cr | 29 | 0 | 0 | 2.0% | 2.0% | — |
| Aug 2025 | ₹3,107 Cr | 29 | 0 | 0 | 2.2% | 2.2% | — |
| Jul 2025 | ₹3,190 Cr | 29 | 0 | 0 | 1.8% | 1.8% | — |
| Jun 2025 | ₹3,057 Cr | 29 | 0 | 1 | 1.1% | 1.1% | — |
| May 2025 | ₹2,961 Cr | 30 | 0 | 0 | 0.4% | 0.4% | — |
| Apr 2025 | ₹2,912 Cr | 30 | 0 | 0 | 0.1% | 0.1% | — |
| Mar 2025 | ₹3,019 Cr | 30 | 0 | 1 | 0.8% | 0.8% | — |
| Feb 2025 | ₹2,951 Cr | 31 | 0 | 0 | 1.7% | 1.7% | — |
| Jan 2025 | ₹3,198 Cr | 31 | 1 | 0 | 0.8% | 0.8% | — |
| Dec 2024 | ₹3,340 Cr | 30 | 1 | 0 | 2.5% | 2.5% | — |
| Nov 2024 | ₹3,249 Cr | 29 | 0 | 0 | 4.8% | 4.8% | — |
| Oct 2024 | ₹3,138 Cr | 29 | 1 | 0 | 2.7% | 2.7% | — |
For any of the 70 earlier months, choose it in “Portfolio as of” at the top of the page.